# Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis

> **NCT06716281** · PHASE3 · RECRUITING · sponsor: **Shanghai IxCell Biotechnology Co., LTD** · enrollment: 398 (estimated)

## Conditions studied

- Knee Osteoarthritis

## Interventions

- **BIOLOGICAL:** Human umbilical cord mesenchymal stem cells
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06716281
- **Lead sponsor:** Shanghai IxCell Biotechnology Co., LTD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-05
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 398 (ESTIMATED)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716281, "Efficacy and Safety of IxCell hUC-MSC-O in Patients With Knee Osteoarthritis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06716281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*